Skip Navigation

Acute Liver Failure

printer friendly version


Acute liver failure (ALF) and acute liver injury (ALI) observational study

 

Enrollment Status: OPEN

A multi-center NIH study initiated in 1997 that is looking at acute liver failure and severe acute liver injury in adults. The aim of this study is to gather prospective demographic and clinical data on patients with acute liver failure and acute liver injury with varying etiologies.

Inclusion criteria

Informed consent may be obtained from family member.

Blood and urine samples, clinical data, and survival will be obtained x 7 days.

Patients are invited for a return visit at 6 and 12 months to assess long-term outcomes. Participants will receive $30 for each return visit.

Contacts for referrals and questions: Please see below.


STOP–ALF: A phase 2a study to evaluate the safety and tolerability of OCR-002 (ornithine phenylacetate) in the treatment of patients with acute liver failure/severe acute liver injury

 

Enrollment Status: OPEN

The goal of the STOP–ALF protocol is to evaluate the safety and tolerability of OCR-002 (ornithine phenylacetate) to reduce venous ammonia levels in patients with ALF or severe liver injury due to acetaminophen overdose.

Inclusion Criteria

Study design


Contacts for referrals and questions for both studies:

Principal Investigator: Robert Fontana, MD – rfontana@med.umich.edu